NHS Approves First New Ovarian Cancer Drug in 20 Years, Extending Survival

Executive Briefing

• Delivers chemotherapy directly to cancer cells via antibody targeting, significantly reducing debilitating side-effects
• Extends average survival from 12.8 months to 16.5 months compared to standard chemotherapy
• Improves quality of life — patients retain hair, receive infusions every three weeks instead of weekly
• Approved by NICE for up to 400 eligible patients annually in England with platinum-resistant ovarian cancer
• Marks the first significant treatment advance for hard-to-treat ovarian cancer in over two decades